Adalimumab inhibits TNF-α, a major proinflammatory cytokine that has a fundamental role in adaptive immune responses, which in turn may lead to increased susceptibility to severe and opportunistic infections or even reactivation of dormant infections[6]. The gene discussed is TNF; the disease is infection.